Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
17 pending office actions • 15 clients • 17 examiners • 11 art units • 0 of 17 (0%) have an AI response strategy ready
Lavery, De Billy, LLP operates in the Biotechnology & Pharmaceuticals technology area, having managed 1574 career applications. The firm has established a resolved allowance rate of 82.58 percent, which reflects the proportion of its applications that reach a grant. This record of 1574 career applications serves as the basis for the firm's experience in the life sciences sector.
The firm's prosecution process involves an average of 2.91 office actions per allowance. This metric indicates the typical number of interactions between the firm and patent examiners before an application reaches an allowance. Currently, the firm has 9 pending office actions, which represent a focused workload within its Biotechnology & Pharmaceuticals practice. These 9 pending office actions are fewer than the 1574 career applications on record.
The 1574 career applications and 82.58 percent allowance rate establish the firm's historical performance. The 2.91 office actions per allowance provide a benchmark for the expected duration of the prosecution process. The 9 pending office actions show the firm's ongoing activity in securing patent rights for its clients.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (18%) |
| §103 only | 5 (29%) |
| Double-patenting + other | 1 (6%) |
| Multi-statute (no §101) | 8 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONTALVO, CARLOS FERNANDO | 1 | 15.0% | -1.1% |
| ALSOMIRI, ISAM A | 1 | 66.7% | +23.5% |
| LIU, TRACY | 1 | 54.5% | +27.3% |
| WILEY, DANIEL J | 1 | 71.5% | +37.6% |
| CASERTO, JULIA SHARON | 1 | 71.4% | +28.9% |
| SHIAO, YIH-HORNG | 1 | 72.5% | +75.9% |
| ANDERSON, FOLASHADE | 1 | 35.2% | +37.4% |
| LAU, JONATHAN S | 1 | 63.7% | -17.3% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 61.1% | +62.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615237 | METHOD, DEVICE, AND COMPUTER-READABLE MEDIUM FOR DISPATCHING A PLURALITY OF AGENTS TO A PLURALITY OF TASKS | ANDERSON, FOLASHADE | 32d overdue |
| 17904677 | USE OF CASTALAGIN OR ANALOGS THEREOF FOR ANTI-CANCER EFFICACY AND TO INCREASE THE RESPONSE TO IMMUNE CHECKPOINT INHIBITORS | HEITMEIER, KENDALL NICOLE | 2d overdue |
| 18614126 | KIT FOR PREVENTING OR TREATING FILOVIRUS AND FLAVIVIRUS DISEASES | LAU, JONATHAN S | 82d |
| 19394215 | COLLABORATIVE FLOW EDITING SYSTEM AND METHOD | MONTALVO, CARLOS FERNANDO | — |
| 18768745 | POROUS MATERIAL AND PROCESS | LIU, TRACY | — |
| 18767062 | FALL PROTECTION SYSTEM | WILEY, DANIEL J | — |
| 18703858 | SYSTEM FOR REPLENISHING AN ON-BOARD POWER SOURCE FOR A PROPULSION SYSTEM ON A VEHICLE SUCH AS A WATERCRAFT AND PROCESS | CASERTO, JULIA SHARON | — |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | SHIAO, YIH-HORNG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18615237 | METHOD, DEVICE, AND COMPUTER-READABLE MEDIUM FOR DISPATCHING A PLURALITY OF AGENTS TO A PLURALITY OF TASKS | ANDERSON, FOLASHADE | 32d overdue |
| 18588829 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | KASSA, TIGABU | 84d |
| 18857077 | A METHOD AND A SYSTEM FOR 3D SURFACE IMAGING | ALSOMIRI, ISAM A | — |
| 18768745 | POROUS MATERIAL AND PROCESS | LIU, TRACY | — |
| 18767062 | FALL PROTECTION SYSTEM | WILEY, DANIEL J | — |
| 18703858 | SYSTEM FOR REPLENISHING AN ON-BOARD POWER SOURCE FOR A PROPULSION SYSTEM ON A VEHICLE SUCH AS A WATERCRAFT AND PROCESS | CASERTO, JULIA SHARON | — |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | SHIAO, YIH-HORNG | — |
| 18576567 | NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1732 | 2 |
| 3629 | 1 |
| 1614 | 1 |
| 3678 | 1 |
| 3623 | 1 |
| 1693 | 1 |
| 1619 | 1 |
| 2881 | 1 |
| 1634 | 1 |
| 1621 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19394215 | COLLABORATIVE FLOW EDITING SYSTEM AND METHOD | Gemba Software Solutions Inc. | MONTALVO, CARLOS FERNANDO | 3629 | §101§103 | Non-Final OA | — | Pending | Nov 19, 2025 |
| 18857077 | A METHOD AND A SYSTEM FOR 3D SURFACE IMAGING | Institut National De La Recherche Scientifique | ALSOMIRI, ISAM A | §103 | Non-Final OA | — | Pending | Oct 15, 2024 | |
| 18768745 | POROUS MATERIAL AND PROCESS | Groupe Ppd Inc. | LIU, TRACY | 1614 | §103§112 | Final Rejection | — | Pending | Jul 10, 2024 |
| 18767062 | FALL PROTECTION SYSTEM | Delta Prevention Inc. | WILEY, DANIEL J | 3678 | §102§103 | Non-Final OA | — | Pending | Jul 09, 2024 |
| 18703858 | SYSTEM FOR REPLENISHING AN ON-BOARD POWER SOURCE FOR A PROPULSION SYSTEM ON A VEHICLE SUCH AS A WATERCRAFT AND PROCESS | Cambria Geosciences Inc. | CASERTO, JULIA SHARON | §102§103 | Non-Final OA | — | Pending | Apr 23, 2024 | |
| 18699854 | METHOD FOR CROSSLINKING HYALURONIC ACID USING RESONANT ACOUSTIC MIXING | Studio Bioscience Inc. | SHIAO, YIH-HORNG | §102§103§112 | Non-Final OA | — | Pending | Apr 09, 2024 | |
| 18615237 | METHOD, DEVICE, AND COMPUTER-READABLE MEDIUM FOR DISPATCHING A PLURALITY OF AGENTS TO A PLURALITY OF TASKS | Humanitas Solutions Inc. | ANDERSON, FOLASHADE | 3623 | §101§102§103 | Final Rejection | 32d overdue | Pending | Mar 25, 2024 |
| 18614126 | KIT FOR PREVENTING OR TREATING FILOVIRUS AND FLAVIVIRUS DISEASES | Her Majesty The Queen In Right Of Canada AS Represented By The Minister Of Health | LAU, JONATHAN S | 1693 | §103§112 | Final Rejection | 82d | Pending | Mar 22, 2024 |
| 18588829 | PUTRESCINE SLOW-RELEASE TOPICAL FORMULATIONS | Vivier Canada Inc. | KASSA, TIGABU | 1619 | §103 | Non-Final OA | 84d | Pending | Feb 27, 2024 |
| 18576567 | NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF | Valorisation Hsj, Limited Partnership | CUNNINGCHEN, KATHLEEN MARY | §101§102§103§112 | Non-Final OA | — | Pending | Jan 04, 2024 | |
| 18567915 | COMBINATION THERAPY FOR THE TREATMENT OF ENTERIC NEUROPATHIES | Transfert Plus, Limited Partnership | CHERNYSHEV, OLGA N | §103DP | Non-Final OA | — | Pending | Dec 07, 2023 | |
| 18492974 | METHOD AND SYSTEM FOR SINGLE-PIXEL IMAGING | Institut National De La Recherche Scientifique | LI, LARRY | 2881 | §103 | Non-Final OA | — | Pending | Oct 24, 2023 |
| 18253465 | USE OF CARRAGEENAN AS A VISCOSITY-MODIFYING ADMIXTURE IN A FLOWABLE CEMENTITIOUS SUSPENSIONS | Socpra Sciences Et Genie S.E.C. | WEISS, PAMELA HL | 1732 | §103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18312672 | SINGLE-ATOM CATALYSTS AND METHOD OF MANUFACTURE THEREOF | Institut National De La Recherche Scientifique | LI, JUN | 1732 | §102§103§112 | Non-Final OA | — | Pending | May 05, 2023 |
| 18030407 | LIVE BIOTHERAPEUTICS SECRETING SYNTHETIC BACTERIOPHAGES IN THE TREATMENT OF CANCER | Tatum Bioscience Inc. | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | 29d | Pending | Apr 05, 2023 |
| 17904677 | USE OF CASTALAGIN OR ANALOGS THEREOF FOR ANTI-CANCER EFFICACY AND TO INCREASE THE RESPONSE TO IMMUNE CHECKPOINT INHIBITORS | VAL-CHUM, LIMITED PARTNERSHIP | HEITMEIER, KENDALL NICOLE | 1621 | §103§112 | Non-Final OA | 2d overdue | Pending | Aug 19, 2022 |
| 17757570 | USE OF GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR (GDNF) FOR THE TREATMENT OF ENTERIC NEUROPATHIES | Transfert Plus, Société En Commandite | NGUYEN, NGHI V | 1653 | §103 | Final Rejection | 8d | Pending | Jun 17, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial